Clinical Trials
98 trials18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Perspective Therapeutics
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
National Cancer Institute (NCI)
DOTATOC PET/CT for Imaging NET Patients
British Columbia Cancer Agency
MK-6482-015
Merck Sharp & Dohme LLC
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
National Institutes of Health Clinical Center (CC)
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Institutes of Health Clinical Center (CC)
PRRT-PGL-PHEO
Azienda USL Reggio Emilia - IRCCS
SJFAMILY
St. Jude Children's Research Hospital
LUPARPED
Fundación de investigación HM
Prospective Cohort Study of Pheochromocytoma/Paraganglioma
Peking Union Medical College Hospital
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
National Institutes of Health Clinical Center (CC)
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
National Institutes of Health Clinical Center (CC)
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
Columbia University
LAMPARA
Columbia University
In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma
Abramson Cancer Center at Penn Medicine
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
Jazz Pharmaceuticals
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
National Institutes of Health Clinical Center (CC)
Development and Clinical Application of a Novel Imaging Grading System for Pheochromocytoma and Paraganglioma (PPGL)
Peking University First Hospital
NETTER-P
Advanced Accelerator Applications
PHEO
University Hospital, Rouen
Spencer
Enterome
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
Institutional Registry of Rare Diseases
Hospital Italiano de Buenos Aires
Multicenter Study on Cardiovascular and Metabolic Complications in Patients With Biochemically Silent Pheochromocytomas and Paragangliomas
Laikο General Hospital, Athens
Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma
Peking Union Medical College Hospital
DOMINO-START
Weill Medical College of Cornell University
Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial
National Cancer Institute (NCI)
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
The University of Texas Health Science Center at San Antonio
Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma
Nanjing First Hospital, Nanjing Medical University
Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal Tumors
Peking University First Hospital
BELIEVE-VHL
AC Camargo Cancer Center
Ivonescimab in the Treatment of Multiple Advanced Tumors
Fudan University
Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Using the EHR to Advance Genomic Medicine Across a Diverse Health System
University of Pennsylvania
PRONO-PARAG
Hospices Civils de Lyon
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma
Seoul National University Hospital
NSAT
Society for Endocrinology
18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
HEPHESTOS
Radboud University Medical Center
Correlation Between Preoperative Images of PPGL and Intraoperative Hemodynamics
Peking Union Medical College Hospital
SNIPP
University Health Network, Toronto
LUFOR
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Universidad Nacional Autonoma de Mexico
The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
Peking Union Medical College Hospital
The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocytoma or Paraganglioma (PPGLs)
King's College Hospital NHS Trust